This HTML5 document contains 225 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/chebi/
n16http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n34http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/wikipedia/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/kegg-compound/
n17http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n33http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/pubchem-substance/
n27http://www.rxlist.com/cgi/generic/
n5http://linked.opendata.cz/resource/drugbank/patent/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/kegg-drug/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/iuphar/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/guide-to-pharmacology/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00669/identifier/chemspider/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00669
rdf:type
n3:Drug
n3:description
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).
n3:dosage
n8:271B4081-363D-11E5-9242-09173F13E4C5 n8:271B4082-363D-11E5-9242-09173F13E4C5 n8:271B4083-363D-11E5-9242-09173F13E4C5 n8:271B4084-363D-11E5-9242-09173F13E4C5 n8:271B407D-363D-11E5-9242-09173F13E4C5 n8:271B407E-363D-11E5-9242-09173F13E4C5 n8:271B407F-363D-11E5-9242-09173F13E4C5 n8:271B4080-363D-11E5-9242-09173F13E4C5 n8:271B4089-363D-11E5-9242-09173F13E4C5 n8:271B4085-363D-11E5-9242-09173F13E4C5 n8:271B4086-363D-11E5-9242-09173F13E4C5 n8:271B4087-363D-11E5-9242-09173F13E4C5 n8:271B4088-363D-11E5-9242-09173F13E4C5 n8:271B4079-363D-11E5-9242-09173F13E4C5 n8:271B407A-363D-11E5-9242-09173F13E4C5 n8:271B407B-363D-11E5-9242-09173F13E4C5 n8:271B407C-363D-11E5-9242-09173F13E4C5 n8:271B4078-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Nikai T, Basbaum AI, Ahn AH: Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain. 2008 Oct 31;139(3):533-40. Epub 2008 Aug 23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18723285
n3:group
approved investigational
n3:halfLife
2.5 hours
n3:indication
For the treatment of migraine attacks with or without aura.
n3:manufacturer
n6:271B404C-363D-11E5-9242-09173F13E4C5 n6:271B4049-363D-11E5-9242-09173F13E4C5 n6:271B404D-363D-11E5-9242-09173F13E4C5 n6:271B404A-363D-11E5-9242-09173F13E4C5 n6:271B404B-363D-11E5-9242-09173F13E4C5 n6:271B4050-363D-11E5-9242-09173F13E4C5 n6:271B4051-363D-11E5-9242-09173F13E4C5 n6:271B404E-363D-11E5-9242-09173F13E4C5 n6:271B404F-363D-11E5-9242-09173F13E4C5 n6:271B4054-363D-11E5-9242-09173F13E4C5 n6:271B4055-363D-11E5-9242-09173F13E4C5 n6:271B4052-363D-11E5-9242-09173F13E4C5 n6:271B4053-363D-11E5-9242-09173F13E4C5 n6:271B4056-363D-11E5-9242-09173F13E4C5 n6:271B4057-363D-11E5-9242-09173F13E4C5 n6:271B405A-363D-11E5-9242-09173F13E4C5 n6:271B405B-363D-11E5-9242-09173F13E4C5 n6:271B4058-363D-11E5-9242-09173F13E4C5 n6:271B4059-363D-11E5-9242-09173F13E4C5 n6:271B405E-363D-11E5-9242-09173F13E4C5 n6:271B405C-363D-11E5-9242-09173F13E4C5 n6:271B405D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00669 n17:DB00669
dcterms:title
Sumatriptan
adms:identifier
n15:Sumatriptan n22:5165 n23:DB00669 n24:10650 n25:119 n26:C07319 n28:119 n29:PA451566 n30:5358 n31:D00451 n32:0173-0524-00 n33:46506520
n3:mechanismOfAction
The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release.
n3:packager
n6:271B4015-363D-11E5-9242-09173F13E4C5 n6:271B4016-363D-11E5-9242-09173F13E4C5 n6:271B4013-363D-11E5-9242-09173F13E4C5 n6:271B4014-363D-11E5-9242-09173F13E4C5 n6:271B4011-363D-11E5-9242-09173F13E4C5 n6:271B4012-363D-11E5-9242-09173F13E4C5 n6:271B400F-363D-11E5-9242-09173F13E4C5 n6:271B4010-363D-11E5-9242-09173F13E4C5 n6:271B400D-363D-11E5-9242-09173F13E4C5 n6:271B400E-363D-11E5-9242-09173F13E4C5 n6:271B400B-363D-11E5-9242-09173F13E4C5 n6:271B400C-363D-11E5-9242-09173F13E4C5 n6:271B4009-363D-11E5-9242-09173F13E4C5 n6:271B400A-363D-11E5-9242-09173F13E4C5 n6:271B4007-363D-11E5-9242-09173F13E4C5 n6:271B4008-363D-11E5-9242-09173F13E4C5 n6:271B4005-363D-11E5-9242-09173F13E4C5 n6:271B4006-363D-11E5-9242-09173F13E4C5 n6:271B4003-363D-11E5-9242-09173F13E4C5 n6:271B4004-363D-11E5-9242-09173F13E4C5 n6:271B4001-363D-11E5-9242-09173F13E4C5 n6:271B4002-363D-11E5-9242-09173F13E4C5 n6:271B4000-363D-11E5-9242-09173F13E4C5 n6:271B4048-363D-11E5-9242-09173F13E4C5 n6:271B4046-363D-11E5-9242-09173F13E4C5 n6:271B4047-363D-11E5-9242-09173F13E4C5 n6:271B4044-363D-11E5-9242-09173F13E4C5 n6:271B4045-363D-11E5-9242-09173F13E4C5 n6:271B403F-363D-11E5-9242-09173F13E4C5 n6:271B4043-363D-11E5-9242-09173F13E4C5 n6:271B403D-363D-11E5-9242-09173F13E4C5 n6:271B403E-363D-11E5-9242-09173F13E4C5 n6:271B403B-363D-11E5-9242-09173F13E4C5 n6:271B403C-363D-11E5-9242-09173F13E4C5 n6:271B4039-363D-11E5-9242-09173F13E4C5 n6:271B403A-363D-11E5-9242-09173F13E4C5 n6:271B4037-363D-11E5-9242-09173F13E4C5 n6:271B4038-363D-11E5-9242-09173F13E4C5 n6:271B4033-363D-11E5-9242-09173F13E4C5 n6:271B4034-363D-11E5-9242-09173F13E4C5 n6:271B4031-363D-11E5-9242-09173F13E4C5 n6:271B4032-363D-11E5-9242-09173F13E4C5 n6:271B402D-363D-11E5-9242-09173F13E4C5 n6:271B402E-363D-11E5-9242-09173F13E4C5 n6:271B402B-363D-11E5-9242-09173F13E4C5 n6:271B402C-363D-11E5-9242-09173F13E4C5 n6:271B4029-363D-11E5-9242-09173F13E4C5 n6:271B402A-363D-11E5-9242-09173F13E4C5 n6:271B4027-363D-11E5-9242-09173F13E4C5 n6:271B4028-363D-11E5-9242-09173F13E4C5 n6:271B4025-363D-11E5-9242-09173F13E4C5 n6:271B4026-363D-11E5-9242-09173F13E4C5 n6:271B4023-363D-11E5-9242-09173F13E4C5 n6:271B4024-363D-11E5-9242-09173F13E4C5 n6:271B4021-363D-11E5-9242-09173F13E4C5 n6:271B4022-363D-11E5-9242-09173F13E4C5 n6:271B401F-363D-11E5-9242-09173F13E4C5 n6:271B4020-363D-11E5-9242-09173F13E4C5 n6:271B401D-363D-11E5-9242-09173F13E4C5 n6:271B401E-363D-11E5-9242-09173F13E4C5 n6:271B401B-363D-11E5-9242-09173F13E4C5 n6:271B401C-363D-11E5-9242-09173F13E4C5 n6:271B4019-363D-11E5-9242-09173F13E4C5 n6:271B401A-363D-11E5-9242-09173F13E4C5 n6:271B4017-363D-11E5-9242-09173F13E4C5 n6:271B4018-363D-11E5-9242-09173F13E4C5 n6:271B4030-363D-11E5-9242-09173F13E4C5 n6:271B402F-363D-11E5-9242-09173F13E4C5 n6:271B4041-363D-11E5-9242-09173F13E4C5 n6:271B4042-363D-11E5-9242-09173F13E4C5 n6:271B4036-363D-11E5-9242-09173F13E4C5 n6:271B4040-363D-11E5-9242-09173F13E4C5 n6:271B4035-363D-11E5-9242-09173F13E4C5
n3:patent
n5:6135979 n5:2469019 n5:5705520 n5:2098302
n3:routeOfElimination
Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan.
n3:synonym
3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide Sumax Sumatriptan Sumatriptán NP101 Imitrex 3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide (3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide Sumatran triptan Imigran Sumatriptan Succinate 1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide Sumatriptanum
n3:toxicity
Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
n3:volumeOfDistribution
* 2.7 L/kg [subcutaneous dosing]
n9:hasAHFSCode
n16:28-32-28
n3:mixture
n34:271B3FFF-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
14%-21%
n3:salt
n3:synthesisReference
Rajeev Mathur, T. Kumar, Sunilendu Roy, Rajiv Malik, "Taste masked sumatriptan tablets and processes for their preparation." U.S. Patent US20060233875, issued October 19, 2006.
n18:hasConcept
n19:M0027392
foaf:page
n21:sumatriptan.html n27:sumitr.htm
n3:IUPAC-Name
n7:271B408E-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4094-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4093-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4090-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4091-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4092-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B408C-363D-11E5-9242-09173F13E4C5 n7:271B40A4-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B408A-363D-11E5-9242-09173F13E4C5 n7:271B408D-363D-11E5-9242-09173F13E4C5 n7:271B40A6-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B408B-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N02CC01
n3:H-Bond-Acceptor-Count
n7:271B409A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B409B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4095-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4096-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4098-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4097-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4099-363D-11E5-9242-09173F13E4C5
n3:absorption
Approximately 15%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
103628-46-2
n3:category
n3:clearance
* 1200 mL/min [Following a 6-mg SC injection]
n3:containedIn
n4:271B4063-363D-11E5-9242-09173F13E4C5 n4:271B4061-363D-11E5-9242-09173F13E4C5 n4:271B4062-363D-11E5-9242-09173F13E4C5 n4:271B405F-363D-11E5-9242-09173F13E4C5 n4:271B4060-363D-11E5-9242-09173F13E4C5 n4:271B4077-363D-11E5-9242-09173F13E4C5 n4:271B4075-363D-11E5-9242-09173F13E4C5 n4:271B4076-363D-11E5-9242-09173F13E4C5 n4:271B406E-363D-11E5-9242-09173F13E4C5 n4:271B406F-363D-11E5-9242-09173F13E4C5 n4:271B406C-363D-11E5-9242-09173F13E4C5 n4:271B406D-363D-11E5-9242-09173F13E4C5 n4:271B406A-363D-11E5-9242-09173F13E4C5 n4:271B406B-363D-11E5-9242-09173F13E4C5 n4:271B4068-363D-11E5-9242-09173F13E4C5 n4:271B4069-363D-11E5-9242-09173F13E4C5 n4:271B4066-363D-11E5-9242-09173F13E4C5 n4:271B4067-363D-11E5-9242-09173F13E4C5 n4:271B4064-363D-11E5-9242-09173F13E4C5 n4:271B4065-363D-11E5-9242-09173F13E4C5 n4:271B4074-363D-11E5-9242-09173F13E4C5 n4:271B4072-363D-11E5-9242-09173F13E4C5 n4:271B4073-363D-11E5-9242-09173F13E4C5 n4:271B4070-363D-11E5-9242-09173F13E4C5 n4:271B4071-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B40A0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B40A2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B40A3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B40A5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B409F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B409E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B40A1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B408F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B409C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B409D-363D-11E5-9242-09173F13E4C5